Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Brief Summary: This randomized phase III trial studies carboplatin, paclitaxel, and bevacizumab to see how well they work compared to carboplatin, paclitaxel, and placebo in treating patients with stage III or stage IV ovarian epithelial, primary peritoneal, or fallopian tube cancer. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. It is not yet known whether carboplatin, paclitaxel, and bevacizumab are more effective than carboplatin, paclitaxel, and placebo in treating ovarian epithelial, primary peritoneal, or fallopian tube cancer.


Options:
A: Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: neoadjuvant therapy; Assigned to Arm(s): N/A
B: Arm Label: Arm I PDS and chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: PDS (Primary Debulkdung Surgery), Procedure: 6 cycles of standard chemotherapy | Arm Label: Arm II Timing of surgery after 3 cycles of SOC CTX; Type: EXPERIMENTAL; Interventions: Procedure: Timing of surgery after 3 cycles of standard NACT, IDS, Procedure: IDS, Drug: 3 cycles of standard chemotherapy | Intervention Type: PROCEDURE; Name: PDS (Primary Debulkdung Surgery); Assigned to Arm(s): Arm I PDS and chemotherapy | Intervention Type: PROCEDURE; Name: 6 cycles of standard chemotherapy; Assigned to Arm(s): Arm I PDS and chemotherapy | Intervention Type: PROCEDURE; Name: Timing of surgery after 3 cycles of standard NACT, IDS; Assigned to Arm(s): Arm II Timing of surgery after 3 cycles of SOC CTX | Intervention Type: PROCEDURE; Name: IDS; Assigned to Arm(s): Arm II Timing of surgery after 3 cycles of SOC CTX | Intervention Type: DRUG; Name: 3 cycles of standard chemotherapy; Assigned to Arm(s): Arm II Timing of surgery after 3 cycles of SOC CTX
C: Arm Label: Primary debulking surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Primary Debulking Surgery + Adjuvant Chemotherapy | Arm Label: Interval debulking surgery; Type: EXPERIMENTAL; Interventions: Drug: Neoadjuvant chemotherapy + Interval Debulking Surgery | Intervention Type: DRUG; Name: Neoadjuvant chemotherapy + Interval Debulking Surgery; Assigned to Arm(s): Interval debulking surgery | Intervention Type: PROCEDURE; Name: Primary Debulking Surgery + Adjuvant Chemotherapy; Assigned to Arm(s): Primary debulking surgery
D: Arm Label: Arm I (placebo, paclitaxel, carboplatin); Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Other: Placebo, Other: Quality-of-Life Assessment | Arm Label: Arm II (placebo, paclitaxel, carboplatin, bevacizumab); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Drug: Carboplatin, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Other: Placebo, Other: Quality-of-Life Assessment | Arm Label: Arm III (paclitaxel, carboplatin, bevacizumab); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Drug: Carboplatin, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Other: Quality-of-Life Assessment | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): Arm II (placebo, paclitaxel, carboplatin, bevacizumab), Arm III (paclitaxel, carboplatin, bevacizumab) | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm I (placebo, paclitaxel, carboplatin), Arm II (placebo, paclitaxel, carboplatin, bevacizumab), Arm III (paclitaxel, carboplatin, bevacizumab) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (placebo, paclitaxel, carboplatin), Arm II (placebo, paclitaxel, carboplatin, bevacizumab), Arm III (paclitaxel, carboplatin, bevacizumab) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm I (placebo, paclitaxel, carboplatin), Arm II (placebo, paclitaxel, carboplatin, bevacizumab), Arm III (paclitaxel, carboplatin, bevacizumab) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Arm I (placebo, paclitaxel, carboplatin), Arm II (placebo, paclitaxel, carboplatin, bevacizumab) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Arm I (placebo, paclitaxel, carboplatin), Arm II (placebo, paclitaxel, carboplatin, bevacizumab), Arm III (paclitaxel, carboplatin, bevacizumab)

Answer: D